ORBi: Detailled Reference

Article (Scientific journals)

Quinze ans d'anti-TNF dans la maladie de Crohn: comment tirer le meilleur de cette revolution therapeutique?

Louis, Edouard; REENAERS, Catherine; Meuwis, Marie-Alice et al.

2012 • In Revue Médicale de Liège, 67 Spec No, p. 8-13

Peer reviewed

Permalink
https://hdl.handle.net/2268/138701

PubMed
22690480

Files (1)Send to Details Statistics Bibliography Similar publications

Files

Full Text

2012-Quinze ans d'anti-TNF... révolution thérapeutique-RMLg-PostPE.pdf

Publisher postprint (215.56 kB)

All documents in ORBi are protected by a user license.

Send to

RIS BibTex APA Chicago Permalink X Linkedin

Details

Keywords :

Antibodies, Monoclonal/therapeutic use; Crohn Disease/drug therapy; Gastrointestinal Agents/therapeutic use; Humans; Severity of Illness Index; Tumor Necrosis Factor-alpha/antagonists & inhibitors

Abstract :

[en] After fifteen years of use, the anti-TNF antibodies have become the corner stone of the treatment of moderate and severe Crohn's disease. The skill acquired over the years through experimental trials and clinical experience leads to increased therapeutic efficacy and minimized risks. These antibodies are introduced increasingly earlier in Crohn's disease as well as in a broader range of patients, aiming at changing the natural history of the diseases by avoiding the development of intestinal tissue damage and complications.

Disciplines :

Gastroenterology & hepatology

Author, co-author :

Louis, Edouard ; Université de Liège - ULiège > Département des sciences cliniques > Hépato-gastroentérologie

REENAERS, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

Meuwis, Marie-Alice ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

VAN KEMSEKE, Catherine ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

LATOUR, Pascale ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

CHAPELIER, Nathalie ; Centre Hospitalier Universitaire de Liège - CHU > Rhumatologie

WERTZ, Sylvie ; Centre Hospitalier Universitaire de Liège - CHU > Gastro-Entérologie-Hépatologie

COIMBRA MARQUES, Carla ; Centre Hospitalier Universitaire de Liège - CHU > Chirurgie abdominale- endocrinienne et de transplantation

MEUNIER, Paul ; Centre Hospitalier Universitaire de Liège - CHU > Imagerie abdominale

Belaiche, Jacques ; Université de Liège - ULiège > Département des sciences cliniques > Département des sciences cliniques

Language :

French

Title :

Quinze ans d'anti-TNF dans la maladie de Crohn: comment tirer le meilleur de cette revolution therapeutique?

Alternative titles :

[en] Fifteen years of use of anti-TNF antibodies in moderate to severe Crohn's disease: how to make the best of this experience

Publication date :

March 2012

Journal title :

Revue Médicale de Liège

ISSN :

0370-629X

eISSN :

2566-1566

Publisher :

Université de Liège. Revue Médicale de Liège, Liège, Belgium

Volume :

67 Spec No

Pages :

8-13

Peer reviewed :

Peer reviewed

Available on ORBi :

since 14 January 2013

Statistics

Number of views

290 (14 by ULiège)

Number of downloads

719 (13 by ULiège)

More statistics

Scopus citations^®

0

Scopus citations^®
without self-citations

0

Bibliography

Targan SR, Hanauer SB, van Deventer SJ, et al. - A short-term study of chimeric monoclonal antibody cA2 to tumor necrosis factor alpha for Crohn's disease. Crohn's Disease cA2 Study Group. N Engl J Med, 1997, 337, 1029-1035.
Hanauer SB, Feagan BG, Lichtenstein GR, et al., ACCENT I Study Group. - Maintenance infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet, 2002, 359, 1541-1549. (Pubitemid 34621118)
Colombel JF, Sandborn WJ, Rutgeerts P, et al. - Comparison of two adalimumab treatment schedule strategies for moderate-to-severe Crohn's disease : results from the CHARM trial. Am J Gastroenterol, 2009, 104, 1170-1179.
Schreiber S, Khaliq-Kareemi M, Lawrance IC, et al., PRECISE 2 Study Investigators. - Maintenance therapy with certolizumab pegol for Crohn's disease. N Engl J Med, 2007, 357, 239-250. (Pubitemid 47080388)
Sands BE, Anderson FH, Bernstein CN, et al. - Infliximab maintenance therapy for fistulizing Crohn's disease. N Engl J Med, 2004, 350, 876-885. (Pubitemid 38252535)
Sandborn WJ, Panaccione R, Thakkar R, et al. - Crohn's disease mucosal healing in adalimumab-treated patients is affected by disease duration : results from EXTEND. Gastroenterology, 2010, 138, 164.
Löfberg R, Louis E, Reinisch W, et al. - Adalimumab produces clinical remission and reduces extraintestinal manifestations in Crohn's disease : results from CARE. Inflamm Bowel Dis, 2012, 18, 1-9.
Binion DG, Louis E, Oldenburg B, et al. - Effect of adalimumab on work productivity and indirect costs in moderate to severe Crohn's disease : a meta-analysis. Can J Gastroenterol, 2011, 25, 492-496.
Lee TW, Fedorak RN. -Tumor necrosis factor-á monoclonal antibodies in the treatment of inflammatory bowel disease : clinical practice pharmacology. Gastroenterol Clin North Am, 2010, 39, 543-557.
Rahier JF, Moreels T, De Munter P, et al. - Prevention of opportunistic infections in patients with inflammatory bowel disease and implications of the ECCO consensus in Belgium. Acta Gastroenterol Belg, 2010, 73, 41-45.
Rahier JF, Moutschen M, Van Gompel A, et al. - Vaccinations in patients with immune-mediated inflammatory diseases. Rheumatology, 2010, 49, 1815-1827
Rahier JF, Papay P, Salleron J, et al.; European Crohn's and Colitis Organisation (ECCO). - H1N1 vaccines in a large observational cohort of patients with inflammatory bowel disease treated with immunomodulators and biological therapy. Gut, 2011, 60, 456-462.
Allez M, Karmiris K, Louis E, et al. - Report of the ECCO pathogenesis workshop on anti-TNF therapy failures in inflammatory bowel diseases : definitions, frequency and pharmacological aspects. J Crohns Colitis, 2010, 4, 355-366.
Louis E, Belaiche J, Reenaers C. - Anti-tumor necrosis factor nonresponders in Crohn's disease : therapeutic strategies. Dig Dis, 2009, 27, 351-357.
Louis E, Vermeire S, Rutgeerts P, et al. - A positive response to infliximab in Crohn's disease is associated with a higher systemic inflammation before treatment but not with -308 TNF gene polymorphism. Scand J Gastroenterol, 2002, 37, 818-824. (Pubitemid 34836819)
Willot S, Vermeire S, Ohresser M, et al. - No association between C-reactive protein gene polymorphisms and decrease of C-reactive protein serum concentration after infliximab treatment in Crohn's disease. Pharmacogenet Genomics, 2006, 16, 37-42. (Pubitemid 41803875)
Dideberg V, Farnir F, Vermeire S, et al. - The TNF/ADAM 17 system: implication of an ADAM 17 haplotype in the clinical response to infliximab in Crohn's disease. Pharmacogenet Genommics, 2006, 16, 727-734. (Pubitemid 44454867)
Louis E, Watier H, Schreiber S, et al. - Polymorphism in IgG Fc receptor gene FCGR3A and response to infliximab in Crohn's disease: a subanalysis of the ACCENT I study. Pharmacogenet and Genomics, 2006, 16, 911-914. (Pubitemid 44772809)
Dideberg V, Louis E, Farnir F, et al. - Lymphotoxin alpha gene in Crohn's disease patients : absence of implication in the response to infliximab in a large cohort study. Pharmacogenet Genomics, 2006, 16, 369-373.
Vermeire S, Louis E, Rutgeerts P, et al. - NOD2/CARD15 does not influence response to infliximab in Crohn's disease. Gastroenterology, 2002, 123, 106-111. (Pubitemid 34747530)
Meuwis MA, Fillet M, Lutteri L, et al. - Proteomics for prediction and characterization of response to infliximab in Crohn's disease : a pilot study. Clin Biochem, 2008, 41, 960-967.
Louis E, Panés J. - Adalimumab in ulcerative colitis: can pharmacodynamics be improved based on pharmacokinetics? Gastroenterology, 2012, 142, 176-178.
Kopylov U, Mantzaris GJ, Katsanos KH, et al. - The efficacy of shortening the dosing interval to once every six weeks in Crohn's patients losing response to maintenance dose of infliximab. Aliment Pharmacol Ther, 2011, 33, 349-357.
Pariente B, de Chambrun GP, Krzysiek R, et al. - Trough levels and antibodies to infliximab may not predict response to intensification of infliximab therapy in patients with inflammatory bowel disease. Inflamm Bowel Dis, 2011, Aug 29. doi: 10.1002/ibd.21839. [Epub ahead of print]
Karmiris K, Paintaud G, Noman M, et al. - Influence of trough serum levels and immunogenicity on long-term outcome of adalimumab therapy in Crohn's disease. Gastroenterology, 2009, 137, 1628-1640.
Colombel JF, Sandborn WJ, Reinisch W, et al., SONIC Study Group. - Infliximab, azathioprine, or combination therapy for Crohn's disease. N Engl J Med, 2010, 362, 1383-1395.
Louis E, Collard A, Oger A. - Behaviour of Crohn's disease according to the Vienna classification : changing pattern over the course of the disease. Gut, 2001, 49, 777-782. (Pubitemid 33096034)
Pariente B, Cosnes J, Danese S, et al. - Development of the Crohn's disease digestive damage score, the Lémann score. Inflamm Bowel Dis, 2011, 17, 1415-1422.
Veny M, Esteller M, Ricart E, et al. - Late Crohn's disease patients present an increase in peripheral Th17 cells and cytokine production compared with early patients. Aliment Pharmacol Ther, 2010, 31, 561-572.
Schreiber S, Colombel JF, Bloomfield R, PRECISE 2 Study Investigators. - Increased response and remission rates in short-duration Crohn's disease with subcutaneous certolizumab pegol : an analysis of PRECISE 2 randomized maintenance trial data. Am J Gastroenterol, 2010, 105, 1574-1582.
D'Haens G, Baert F, van Assche G, Belgian Inflammatory Bowel Disease Research Group, North-Holland Gut Club. - Early combined immunosuppression or conventional management in patients with newly diagnosed Crohn's disease : an open randomised trial. Lancet, 2008, 371, 660-667. (Pubitemid 351284485)
Solberg IC, Vatn MH, Høie O, IBSEN Study Group. - Clinical course in Crohn's disease : results of a Norwegian population-based ten-year follow-up study. Clin Gastroenterol Hepatol, 2007, 5, 1430-1438. (Pubitemid 350181602)
Loly C, Belaiche J, Louis E. - Predictors of severe Crohn's disease. Scand J Gastroenterol, 2008, 43, 948-954.
Louis E, Belaiche J, Reenaers C. - Do clinical factors help to predict disease course in inflammatory bowel disease? World J Gastroenterol, 2010, 16, 2600-2603.
Regueiro M, Schraut W, Baidoo L, et al. - Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology, 2009, 136, 441-450.
Louis E, Mary JY, Vernier-Massouille G, et le Groupe d'Etudes Thérapeutiques des Affections Inflammatoires Digestives. - Maintenance of remission among patients with Crohn's disease on antimetabolite therapy after infliximab therapy is stopped. Gastroenterology, 2012, 142, 63-70.

Similar publications